Dual immunotherapy for advanced HCC leverages the synergistic action of cytotoxic T lymphocyte-associated antigen-4 and PD-L1 monoclonal antibodies to activate T cells, resulting in their rapid activation and extensive proliferation [38]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.